TTP Inhibitors
TTP inhibitors constitute a class of chemical compounds designed to modulate the activity of tristetraprolin (TTP), a key player in post-transcriptional regulation. While direct TTP inhibitors are limited, various chemicals offer insights into the intricate regulatory pathways governing TTP expression and function. Dexamethasone, a glucocorticoid, indirectly modulates TTP by activating the glucocorticoid receptor and increasing MAPK phosphatase 1 (MKP-1) expression. MKP-1 deactivates p38 MAPK, a critical activator of TTP, resulting in the stabilization of TTP target mRNAs and influencing inflammatory responses. Similarly, SB203580, a selective p38 MAPK inhibitor, directly interferes with the p38 MAPK pathway associated with TTP activation, providing researchers with a tool to dissect the role of p38 MAPK in TTP-mediated mRNA decay.
Natural compounds like Triptolide and Celastrol indirectly impact TTP by suppressing NF-κB activation, leading to reduced inflammatory responses and modulation of TTP-mediated mRNA decay. TPCA-1 and BAY 11-7082 target the NF-κB pathway by inhibiting IKK-2 and preventing IκBα degradation, indirectly influencing TTP expression and function. JNK Inhibitor VIII and Parthenolide offer insights into the role of JNK and NF-κB, respectively, in TTP-mediated mRNA decay. Amlexanox, an IKKε inhibitor, indirectly modulates TTP expression by inhibiting IKKε, providing a specific tool for investigating the interplay between IKKε signaling and TTP-mediated mRNA decay. In conclusion, TTP inhibitors, though limited in direct options, offer a diverse set of compounds to explore the complex regulatory mechanisms governing TTP activity and its impact on post-transcriptional control. The indirect modulation of TTP through various pathways provides a comprehensive approach to unraveling the intricate interplay between signaling cascades and TTP-mediated mRNA decay in the context of inflammatory responses.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a selective p38 MAPK inhibitor, directly impacting the pathway associated with TTP activation. By inhibiting p38 MAPK, SB203580 interferes with the phosphorylation and activation of TTP. This direct modulation can lead to the stabilization of TTP target mRNAs, influencing the post-transcriptional regulation of inflammatory mediators and cytokines. | ||||||
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $90.00 $204.00 | 13 | |
Triptolide is a natural product with anti-inflammatory properties that indirectly influences TTP. It inhibits the expression of TNF-α and IL-1β, known targets of TTP, by suppressing the activity of NF-κB. Triptolide's indirect modulation can result in reduced inflammatory responses by influencing TTP-mediated mRNA decay, providing insights into the complex interplay between natural compounds and post-transcriptional regulation. | ||||||
IKK-2 Inhibitor IV | 507475-17-4 | sc-203083 | 500 µg | $133.00 | 12 | |
IKK-2 Inhibitor IV (TPCA-1) is an inhibitor of IKK-2, a component of the NF-κB pathway, indirectly influencing TTP. By inhibiting IKK-2, TPCA-1 suppresses the activation of NF-κB, which regulates TTP expression. This indirect modulation can impact TTP-mediated mRNA decay, influencing the post-transcriptional regulation of inflammatory mediators and cytokines. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
BAY 11-7082 is an inhibitor of NF-κB activation, indirectly influencing TTP. By preventing the phosphorylation and degradation of IκBα, BAY 11-7082 inhibits NF-κB activation and, subsequently, TTP expression. This indirect modulation can impact TTP-mediated mRNA decay, influencing the post-transcriptional regulation of inflammatory mediators and cytokines. | ||||||
PD 169316 | 152121-53-4 | sc-204168 sc-204168A sc-204168B sc-204168C | 1 mg 5 mg 10 mg 25 mg | $88.00 $156.00 $281.00 $461.00 | 3 | |
PD 169316 is a selective p38 MAPK inhibitor that directly impacts the pathway associated with TTP activation. By inhibiting p38 MAPK, PD 169316 interferes with the phosphorylation and activation of TTP. This direct modulation can lead to the stabilization of TTP target mRNAs, influencing the post-transcriptional regulation of inflammatory mediators and cytokines. | ||||||
Celastrol, Celastrus scandens | 34157-83-0 | sc-202534 | 10 mg | $158.00 | 6 | |
Celastrol is a triterpenoid with anti-inflammatory properties that indirectly influences TTP. It inhibits the expression of TNF-α and IL-6 by suppressing the activation of NF-κB. Celastrol's indirect modulation can result in reduced inflammatory responses by influencing TTP-mediated mRNA decay, providing insights into the complex interplay between natural compounds and post-transcriptional regulation. | ||||||
Amlexanox | 68302-57-8 | sc-217630 | 10 mg | $160.00 | 2 | |
Amlexanox is an inhibitor of IκB kinase ε (IKKε), indirectly impacting TTP expression. By inhibiting IKKε, Amlexanox suppresses the activation of NF-κB and subsequently influences TTP expression. This indirect modulation can impact TTP-mediated mRNA decay, providing insights into the role of IKKε in the post-transcriptional regulation of inflammatory mediators and cytokines. | ||||||
JNK Inhibitor VIII | 894804-07-0 | sc-202673 | 5 mg | $272.00 | 2 | |
JNK Inhibitor VIII is a selective inhibitor of c-Jun N-terminal kinase (JNK), directly impacting the pathway associated with TTP activation. By inhibiting JNK, this compound interferes with the phosphorylation and activation of TTP. This direct modulation can lead to the stabilization of TTP target mRNAs, influencing the post-transcriptional regulation of inflammatory mediators and cytokines. | ||||||
Parthenolide | 20554-84-1 | sc-3523 sc-3523A | 50 mg 250 mg | $81.00 $306.00 | 32 | |
Parthenolide is a natural compound with anti-inflammatory properties that indirectly influences TTP. It inhibits the activation of NF-κB, a regulator of TTP expression. Parthenolide's indirect modulation can impact TTP-mediated mRNA decay, leading to reduced inflammatory responses. | ||||||
BMS-345541 | 445430-58-0 | sc-221741 | 1 mg | $312.00 | 1 | |
BMS-345541 is a selective inhibitor of IKK-1, indirectly influencing TTP. By inhibiting IKK-1, BMS-345541 suppresses the activation of NF-κB and, subsequently, TTP expression. This indirect modulation can impact TTP-mediated mRNA decay, providing insights into the role of IKK-1 in the post-transcriptional regulation of inflammatory mediators and cytokines. | ||||||